1.
Invest New Drugs
; 39(5): 1454-1455, 2021 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33913071
RESUMO
Recently, we read a paper "Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma" published in Investigational New Drugs. Quisinostat may be a promising drug candidate for the treatment of esophageal squamous cell carcinoma. However, some problems existing in the methods part of this paper are worthy of comment.